Benefits
Tear production + stability + quality (8-week trial)
In a published dry eye trial, Nutritears vs placebo produced significant improvements in tear production, tear stability, tear quality, and tear osmolarity. Multi-parameter improvement addresses the multifactorial nature of dry eye disease.
75% reduction in artificial tears use
In the same trial, artificial-tears use was significantly reduced in the Nutritears group from 2.47 times per day to 0.73 times per day — a 75% reduction — while placebo use remained largely unchanged. Addresses the primary inconvenience complaint of dry eye sufferers: frequent eye drop dependence.
Reduced ocular inflammation + surface damage
The trial documented reductions in ocular inflammation and ocular surface damage with Nutritears vs placebo. Inflammation drives the dry eye cycle — addressing it directly disrupts the cycle. Combined with tear production and quality improvements, supports comprehensive dry eye management.
Larger trial: 155 adults, speed improvements
A larger sponsored study showed significant improvements in participant-reported ocular symptoms within 2 weeks vs placebo, maintained through the end of the study via the SPEED (Standard Patient Evaluation of Eye Dryness) questionnaire. Well-tolerated with no serious adverse events.
2-week onset for measurable benefits
Some improvements were observed within 2 weeks of supplementation in the published clinical trial. Fast onset for an oral dry eye intervention — addresses consumer expectation for noticeable benefits vs gradual nutrient-based effects. Particularly important for chronic dry eye sufferers seeking alternatives to constant eye drop use.
Tear film homeostasis restoration
Nutritears may help restore tear film homeostasis by addressing the key root causes of dry eyes vs simply supplementing tear volume (the mechanism of artificial tears). The root-cause approach distinguishes from symptomatic management — supports long-term dry eye improvement vs ongoing dependence.
Digital eye strain era — 70% of consumers affected
Nearly 70% of consumers attribute their dry eye symptoms to their use of digital devices. 16.4 million people in the US suffer dry eye symptoms (2013 NHWS). Nutritears addresses this growing concern with a supplemental approach distinct from eye drops or behavioral modifications.
Multi-modal nutritional approach
Three bioactives selected based on mechanism of action to address multifactorial dry eye: lutein/zeaxanthin (antioxidant + macular pigment), curcuminoids (anti-inflammatory), vitamin D3 (immune modulation and tear film). The multi-modal approach addresses the multiple drivers of dry eye vs single-ingredient interventions.
Mechanism of action
Lutein/zeaxanthin antioxidant + blue light filter
Lutein and zeaxanthin (from OmniActive's Lutemax 2020 marigold extract) accumulate in macular pigment, filtering blue light from digital screens and reducing oxidative stress in eye tissues. The carotenoids address both retinal protection and ocular surface antioxidant defense — relevant for the digital eye strain era.
Curcuminoid anti-inflammatory action
Curcuminoids (200 mg) from turmeric have well-characterized anti-inflammatory effects via NF-κB pathway inhibition and other mechanisms. Inflammation drives the dry eye cycle — chronic dry eye is now understood as inflammatory ocular surface disease. Addressing inflammation interrupts the disease process.
Vitamin D3 tear film support
Vitamin D3 (600 IU) supports immune modulation and ocular surface health. Vitamin D deficiency is associated with increased dry eye incidence. The 600 IU dose addresses baseline insufficiency rather than treating acute deficiency. Multi-mechanism eye health support.
Integrative Actives platform — particle size reduction
OmniActive's patent-pending Integrative Actives platform reduces particle size of bioactives plus incorporates bioenhancers to facilitate high bioactive delivery and therapeutic effects in one small softgel. Technology enables the multi-bioactive formulation at therapeutic doses vs requiring multiple capsules.
Tear film homeostasis restoration
Nutritears addresses root causes of dry eye — supporting tear film homeostasis vs simply supplementing tear volume. Multi-modal nutritional approach addresses production, stability, quality, and inflammatory contribution simultaneously. Mechanism supports long-term dry eye improvement.
Clinical trials
Published randomized double-blind placebo-controlled trial evaluating Nutritears in subjects with mild-to-moderate dry eye syndrome (DES). 8-week intervention. Comprehensive dry eye outcomes including tear production, stability, quality, osmolarity, ocular inflammation, surface damage. Published in Ophthalmology and Therapy.
60 people with mild to moderate dry eye syndrome. 8-week intervention with Nutritears or placebo after breakfast.
Significant improvements in tear production, tear stability, tear quality, tear osmolarity. Reductions in ocular inflammation and ocular surface damage. Artificial tears use reduced from 2.47 times/day to 0.73 times/day (75% reduction) — vs unchanged in placebo group. Some improvements observed within 2 weeks. Safe and well-tolerated.
Prospective randomized double-blind parallel placebo-controlled study evaluating NutriTears efficacy and safety in 155 adult participants (aged 18-65, median age 42) with mild dry eye symptoms. 56-day (8-week) intervention. Bausch+Lomb-sponsored confirmatory trial. Standard speed questionnaire outcomes.
155 adults aged 18-65 with mild dry eye symptoms. 56-day intervention with NutriTears (n=77) or placebo (n=78). Artificial tears permitted.
Significant improvements in participant-reported ocular symptoms by day 14 (p<0.05). Significant improvements in frequency and severity of dry eye symptoms (speed questionnaire), maintained to day 56 (p<0.001). NutriTears well-tolerated; no serious adverse events. Restoration of tear film homeostasis by addressing key root causes.
Earlier randomized placebo-controlled human trial involving 59 subjects evaluating Nutritears at the patent-pending bioactive combination. 2-week duration intervention. Foundation study for OmniActive's commercial launch.
59 subjects with occasional dry eye symptoms. 2-week intervention with Nutritears or placebo.
Daily supplementation for 2 weeks resulted in significant improvements in production, stability, and quality of tears by reducing ocular surface damage and tear inflammation. Concluded Nutritears can be used as adjuvant to artificial tears in subjects with dry eye syndrome. Reduction in need for artificial tears is a substantial clinical endpoint.